The FDA last week approved Regeneron Pharmaceuticals, Inc.’s Libtayo in newly diagnosed non-small cell lung cancer (NSCLC). The nod positions Libtayo to directly challenge Merck’s Keytruda, the only other PD-1/L1 inhibitor approved for NSCLC in combination with chemotherapy regardless of PD-L1 expression or histology. As a systemic therapy for NSCLC, Keytruda currently holds covered or better status for 65% of insured lives under the pharmacy benefit. Meanwhile, 86% of insured lives have covered or better access to Keytruda for NSCLC under the medical benefit.
SOURCE: MMIT Analytics, as of 11/9/22